Eli Lilly's Next Generation Weight Loss Drug Clears Crucial Obesity Trial The pharmaceutical industry has long been driven by incremental innovation, but every so often a breakthrough comes along that challenges the status quo and resets the bar for what is possible.
Eli Lilly's next generation weight loss drug, retatrutide, is a prime example of this phenomenon. The results of its Phase 3 trial are nothing short of astonishing. Patients achieved an average weight loss of 28.
3% over 80 weeks – a figure that puts them squarely in the realm of bariatric surgery territory.